385 related articles for article (PubMed ID: 11476170)
1. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
6. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
7. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
8. New trends in peptide receptor radioligands.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Andreae F; Kurtaran A; Dudczak R
Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
10. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
11. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy.
Reubi JC
Q J Nucl Med; 1997 Jun; 41(2):63-70. PubMed ID: 9203845
[TBL] [Abstract][Full Text] [Related]
12. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?
Reubi JC; Waser B; Schmassmann A; Laissue JA
Int J Cancer; 1999 May; 81(3):376-86. PubMed ID: 10209952
[TBL] [Abstract][Full Text] [Related]
13. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.
Reubi JC; Waser B; Schaer JC; Laederach U; Erion J; Srinivasan A; Schmidt MA; Bugaj JE
Eur J Nucl Med; 1998 May; 25(5):481-90. PubMed ID: 9575243
[TBL] [Abstract][Full Text] [Related]
14. Regulatory peptide receptors in human hepatocellular carcinomas.
Reubi JC; Zimmermann A; Jonas S; Waser B; Neuhaus P; Läderach U; Wiedenmann B
Gut; 1999 Nov; 45(5):766-74. PubMed ID: 10517918
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
16. Mack Forster Award Lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients.
Virgolini I
Eur J Clin Invest; 1997 Oct; 27(10):793-800. PubMed ID: 9373755
[TBL] [Abstract][Full Text] [Related]
17. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
19. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
Reubi JC
J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]